PURPOSE: Types of economic analyses used for inhaled anesthetic agents, factors to consider in calculating the cost of inhaled anesthetics, limitations of pharmacoeconomic studies of these agents, and strategies for controlling inhaled anesthetic costs are discussed. SUMMARY: Inhaled anesthetic agents comprise a substantial component of drug budgets. Calculation of the cost of administering an inhaled anesthetic should take into consideration the cost per mL, potency, waste, concentration and duration of gas delivery, fresh gas flow rate, molecular weight, and density. The use of newer inhaled anesthetic agents with low solubility in blood and tissue provides a more rapid recovery from anesthesia than older, more soluble agents, and also provides the same level of control of depth of anesthesia at a lower fresh gas flow rate and possibly a lower cost than older agents at a higher fresh gas flow rate. A more rapid recovery may facilitate fast-track recovery and yield cost savings if it allows the completion of additional surgical cases or allows a reduction in personnel overtime expenses. Interpretation of pharmacoeconomic studies of inhaled anesthetics requires an appreciation of the limitations in methodology and ability to extrapolate results from one setting to another. Pharmacists' efforts to reduce anesthetic waste and collaborate with anesthesiologists to improve the use of these agents can help contain costs, but improving scheduling and efficiency in the operating room has a greater potential to reduce operating room costs. CONCLUSION: Much can be done to control costs of anesthetic agents without compromising availability of these agents and patient care.

 

This article has been cited by other articles:

				ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1368 - 1384. [Full Text] [PDF]

				A. F. Shorr, W. L. Jackson, J. H. Sherner, and L. K. Moores Differences Between Low-Molecular-Weight and Unfractionated Heparin for Venous Thromboembolism Prevention Following Ischemic Stroke: A Metaanalysis Chest, January 1, 2008; 133(1): 149 - 155. [Abstract] [Full Text] [PDF]